Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event
Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) recently announced that their new VP of Business Development, Mark Haden, presented new psychedelic substances at the Canadian Psychedelics Association event. This event was exclusive to medical professionals and focused on novel psychedelic treatments, particularly MEAI, aimed at addressing alcohol-use disorder. The company’s involvement in such exclusive discussions highlights its commitment to promoting its innovative treatments and engaging with potential partners in North America.
- Appointment of Mark Haden as VP Business Development enhances the company's expertise in psychedelic medicine.
- Participation in Canadian Psychedelics Association event increases visibility and credibility among medical professionals.
- None.
The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances"
TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that its newly appointed VP Business Development, psychedelic medicine expert Mr. Mark Haden, presented at the Canadian Psychedelics Association ("CPA") event, that was held earlier this week.
The event included a panel, for physicians and medical professionals only, in the topic of "New Psychedelic Substances".
Mr. Mark Haden presented new psychedelic substances. Among other novel psychedelics, he discussed Clearmind’s innovative psychedelic candidate- MEAI, intended for alcohol-use-disorder.
Receiving an invitation from the CPA is a testimony to Mr. Haden’s expertise and knowledge of the psychedelic field. Participating in exclusive events and panels is part of the Company's efforts to raise awareness to its innovative psychedelic treatments amongst medical professionals, industry and potential partners in North America.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol "CMNDF".
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
FAQ
What was discussed at the Canadian Psychedelics Association event regarding Clearmind Medicine?
Who is the new VP of Business Development at Clearmind Medicine?
What stock symbols are associated with Clearmind Medicine Inc.?
What is the main focus of Clearmind Medicine?
